Navigation Links
A crystal ball for brain cancer?

UCLA researchers have uncovered a new way to scan brain tumors and predict which ones will be shrunk by the drug Avastin -- before the patient ever starts treatment. By linking high water movement in tumors to positive drug response, the UCLA team predicted with 70 percent accuracy which patients' tumors were the least likely to grow six months after therapy.

Bronnie McNabb, 57, considers himself lucky. When his aggressive brain cancer returned after chemotherapy and radiation, his UCLA doctor prescribed the off-label use of Avastin, a drug shown to quell cancers in the breast, colon and lung.

One month later, McNabb's tumors had shrunk by 95 percent. Subsequent brain scans show no trace of his cancer at all. The former marathon runner, ordained minister and father of two says he hasn't felt this good since his diagnosis last winter.

In welcome news for patients like McNabb, the U.S. Food and Drug Administration approved the use of Avastin last month for the treatment of brain cancer. The powerful drug shrinks tumors by choking off their blood supply. Half of patients don't respond to the therapy, though, exposing them to unnecessary side effects and medication costing up to $10,000 per month.

Now UCLA scientists have uncovered a new way to image tumors and forecast which patients, like McNabb, are most likely to benefit from Avastin before starting a single dose of treatment. The findings are published in this month's issue of the journal Radiology.

"Avastin is an expensive drug, yet only 50 percent of patients with recurring brain cancers respond to it," said lead author Dr. Whitney Pope, assistant professor of radiological sciences at the David Geffen School of Medicine at UCLA. "Until now, there has been no good way to identify these patients in advance. Our work is the first to suggest that we can predict which tumors will respond before the patient ever starts therapy."

Pope and his colleagues focused on glioblastoma, the most common and deadly form of adult brain tumor, striking 12,000 Americans a year. Despite therapy with surgery, radiation and chemotherapy, the average glioblastoma patient lives only 12 to 15 months after diagnosis.

Survival rates drop even lower if the tumor returns. Conventional therapies produce little benefit; only 8 to 15 percent of patients survive without tumor growth six months after treatment.

The UCLA team studied 82 patients who had undergone surgery and radiation therapy to remove glioblastoma. Half of the patients received infusions of Avastin every two weeks. All underwent monthly brain scans by magnetic resonance imaging (MRI) to monitor change.

The researchers analyzed the MRI scans of the patients whose tumors returned. Explaining what the team saw requires an understanding of how the tumor creates an independent blood supply.

Cancer cells secrete a growth factor called VEGF that spurs the growth of new blood vessels to supply the tumor with oxygen and nutrients. Avastin blocks VEGF, essentially starving the tumor to death.

This process launches a chain of events that is detectable by MRI. Oxygen-starved cells produce more VEGF, which causes blood vessels to leak fluids into the tumor and surrounding tissue. This results in swelling, which boosts water's ability to move freely in the tumor and brain tissue. As cells disintegrate, they no longer pose a physical barrier to water movement.

"We theorized that tumors with more water motion would also have higher VEGF levels," explained Pope. "Because Avastin targets VEGF, it made sense that the drug would work better in tumors with high levels of the growth factor."

By measuring the amount of water motion within the tumor, the researchers were able to predict with 70 percent accuracy which patients' tumors would progress within six months and which would not. They detected greater water movement in the tumors of those persons who later responded best to Avastin.

"When we realized that high levels of VEGF are linked to greater cell death and increased water movement, we were able to predict the patients' response to Avastin before they began treatment," explained Pope. "We were correct 70 percent of the time. Previously, identifying which patients would respond was like flipping a coin. This is a huge improvement."

The research finding presents clear clinical benefits to the patient, says Pope. "Knowing this information ahead of time will help doctors personalize therapy for each patient and decrease exposure to side effects," he noted.

Pope and his colleagues plan to confirm their findings in a larger study. The team will also test the new method's ability to identify responsive patients prior to surgical removal of their tumor.


Contact: Elaine Schmidt
University of California - Los Angeles

Related medicine news :

1. Elton John, Billy Crystal, Tony Bennett, and Gladys Knight Help Starkey Hearing Foundation Raise More than $5 Million at Annual Fundraiser
2. Bausch & Lomb Receives Approval of Crystalens HD in Quarter Diopter Steps
3. Crystal Heart Award Presented to Telemundo for Coverage of Organ Donation
4. ASGE and ASGE Foundation hold Crystal Awards Dinner as part of Digestive Disease Week
5. Frost & Sullivan Recognizes Zecotek Photonics Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology
6. MSU researcher links cholesterol crystals to cardiovascular attacks
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Authentidate Holding Corp.
8. The New Crystalens HD Gives Many Baby Boomers and Seniors an Opportunity to See Clearly at All Distances while Reducing or Eliminating the Need for Glasses
9. Bausch & Lombs Crystalens to be Featured in Florida Advertising Campaign.
10. UCLA scientists develop crystal ball for personalized cancer treatment
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
Post Your Comments:
Related Image:
A crystal ball for brain cancer?
(Date:10/9/2015)... ... October 09, 2015 , ... The American ... Dean for Graduate Medical Education J. Michael Finley, DO, as the recipient of ... selected for his impact on graduate medical education opportunities for osteopathic residents, and ...
(Date:10/9/2015)... WASHINGTON, NH (PRWEB) , ... October 09, 2015 , ... ... Sore Throat Home Exam Aid, is now available online ( ) – just ... and Prevention (CDC) says officially begins in October. However, for many in the U.S., ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... a special promotion on Invisalign, the orthodontic system that uses clear, plastic aligners. ... are almost invisible against the teeth, which allow patients to complete treatment in ...
(Date:10/9/2015)... ... 09, 2015 , ... The Asthma and Allergy Foundation of America (AAFA) has ... Prevention (CDC) to improve the knowledge and skills of underserved adults with asthma. This ... by the CDC and allows AAFA to continue vital efforts to educate people living ...
(Date:10/9/2015)... Columbus, Ohio (PRWEB) , ... October 09, 2015 ... ... the United States, is welcoming individuals from all walks of life to save ... For the set price of $25 per month per medication, individuals and families ...
Breaking Medicine News(10 mins):
... BEIJING, June 9 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC ... partner in China, Beijing RainEarth Technology Co. Ltd., ("China,RainEarth"), ... of,blood dialysis. , This second ... include: a lower broken membrane rate, a higher gap ...
... issued a position paper on the safety of HCA as ... of extracts and GarCitrin(R). This paper, which reviews and analyzes ... component hydroxycitric acid and its salts, is available to download ... . , , ...
... , WOODCLIFF LAKE, N.J., June 9 Par Pharmaceutical Companies, ... began shipping calcitonin-salmon nasal spray to the trade. Calcitonin-salmon ... . Annual U.S. sales of Miacalcin were approximately $112 ... , , Important information about calcitonin-salmon nasal spray ...
... , Center will be the first in the world to ... to deliver blood and complementary imaging tests for solid tumor ... Canary Foundation, a nonprofit organization that funds research in early ... announced their commitment of $20 million to create the Canary ...
... Electronic Pharmacy Record (EPR) to Integrate with Microsoft(R) HealthVault(TM) ... PDX and have entered into a strategic agreement ... for multiple chain and independent pharmacy clients, available to ... aggregated prescription data. The agreement enables any pharmacy using ...
... Corporation, a leader in improving caregiver workflow in healthcare environments, ... J. Rizzo to its board of directors. , , ... our board to help broaden the business and operating base ... CEO of ThinIdentity. "Both Bill and Carol will bring strong ...
Cached Medicine News:
(Date:10/8/2015)...  The National Heart, Lung and Blood Institute ... Broad Institute of MIT and Harvard to provide ... well as data to support smaller pilots in ... for Precision Medicine (TOPMed) program and serves ... which will use whole genome sequencing to drive ...
(Date:10/8/2015)... 2015 ... "Natural Language Processing Market for Health ... (Rule-Based, Statistical, & Hybrid NLP Solutions), Region ... Africa, Latin America) - Global Forecast to ... --> ) has announced the ...
(Date:10/8/2015)... Oct. 08 2015 ... "Global API Market Outlook 2020" report ... has announced the addition of the "Global ... offering. --> Research and Markets ( ... "Global API Market Outlook 2020" report ...
Breaking Medicine Technology:
... Aug. 31, 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... three upcoming investor conferences.  Dr. Mark A. Sirgo, President ... where he will focus on BDSI,s product pipeline, particularly ... which data from the pivotal Phase 3 efficacy study ...
... 2011 Elbit Imaging Ltd. (NASDAQ: EMITF) ... placed an Investor Relations Presentation relating to its Sources and ... "Investor Relations - Company Presentations -Analysis of Sources and Uses." ... Imaging Ltd. operates in the following principal fields of business: ...
Cached Medicine Technology:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: